Live Breaking News & Updates on Asklepios Biopharmaceuticals
Stay updated with breaking news from Asklepios biopharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bayer AG Published Jan. 21, 2021 Share it Large pharmaceutical companies have made gene therapy a priority with a series of acquisitions over the past several years, a stamp of validation for a field that s pushed through decades of ups and downs. One of the latest buyers is German healthcare conglomerate Bayer, which in October inked a $2 billion deal for North Carolina gene therapy developer Asklepios Biopharmaceuticals, also known as AskBio. For Bayer, the acquisition is part of a broader effort to build a gene and cell therapy division. But the deal is just as noteworthy for AskBio, an unusually large, privately held biotech based on the work of one of gene therapy s pioneers, Jude Samulski. ....
Cell and gene therapies can radically change treatment 13 Jan 2021 Mariecar Jara-Puyod, Senior Reporter Cell and gene therapies combined with the burgeoning digital health and artificial intelligence shall remain to be a nucleus and continually pivot the intensely-competitive pharmaceutical industry, accelerating solutions for improved health and better outcomes. This was emphasised at the “Virtual Pharma Media Day” of the healthcare-agriculture global enterprise Bayer on Wednesday (noon to 2.30 pm, UAE time), attended by 200 journalists from 30 countries. Cell therapy is the delivery or injection of “functioning cells into a patient’s body to achieve a medicinal effect-to prevent, manage or cure a certain illness or to repair and regenerate damaged cells.” ....